Description: Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut.
Home Page: www.rallybio.com
RLYB Technical Analysis
234 Church Street
New Haven,
CT
06510
United States
Phone:
203 859 3820
Officers
| Name | Title |
|---|---|
| Dr. Martin W. MacKay Ph.D. | Co-Founder, CEO & Chairman |
| Dr. Stephen Uden M.B, M.D. | Co- Founder, Pres, COO & Chief Scientific Officer |
| Mr. Jeffrey M. Fryer CPA | Co-Founder, CFO & Treasurer |
| Ms. Ami Bavishi | Head of Investor Relations & Corp. Communications |
| Dr. Steven W. Ryder F.A.C.P, M.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.3859 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-07-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 44 |